ZA71 Stock Chart & Stats
€3.46
€0.00(0.00%)
At close: 4:00 PM EDT
€3.46
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.74 - €5.25
Previous CloseN/A
Volume0.00
Average Volume (3M)223.00
Market Cap
€225.68M
Enterprise Value€167.06M
Total Cash (Recent Filing)€156.27M
Total Debt (Recent Filing)€4.96M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 05, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding103,882,935
10 Day Avg. Volume269
30 Day Avg. Volume223
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.54Price Target Upside320.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.22
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory And Clinical ProgressFDA alignment on a surrogate endpoint, rolling BLA acceptance, and planned Phase 3 initiation materially advance nomlabofusp toward potential approval. This reduces regulatory uncertainty relative to an earlier-stage program and creates a clearer development path for the company’s lead asset.
Lead Program Safety And Biological ActivityThe longer-term open-label data provide evidence of sustained biological effect and manageable tolerability across substantial dosing experience. If maintained in later studies, these characteristics could support patient adoption, regulatory progress, and the commercial viability of nomlabofusp.
Cash Runway And Low LeverageA projected cash runway into the third quarter of 2027 gives Larimar time to advance Phase 3 development and regulatory work without an immediate financing deadline. The company’s modest debt also limits solvency pressure while it remains pre-commercial.
Bears Say
No Commercial Revenue And Widening LossesLarimar has no commercial revenue to offset its expanding research and development base, leaving financial performance dependent on future clinical and regulatory success. Widening losses increase the duration of pre-commercial risk and make earnings power difficult to establish over the next several quarters.
Accelerating Cash BurnThe accelerating operating cash outflow reflects the substantial funding required to develop nomlabofusp and prepare for potential commercialization. Even with projected liquidity, continued negative free cash flow may require additional capital before the business can generate internally funded operations.
Negative Returns And Pressured EquityDeeply negative returns on equity show that the current business is consuming capital without producing shareholder returns, while volatile equity indicates the cumulative effect of losses. This weakens financial resilience and can constrain capital allocation as development spending remains elevated.
Larimar Therapeutics News
ZA71 FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was €1.74 and its highest was €5.25 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is €225.68M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Aug 04, 2026. The company reported -€0.268 earnings per share for the quarter, beating the consensus estimate of -€0.34 by €0.072.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.31.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 103,882,935 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -€0.268 in its last earnings report, beating expectations of -€0.34. Following the earnings report the stock price went up 3.049%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:ZA71
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€14.54 (320.30% Upside)
€14.54 (320.30% Upside)
Blogger Sentiment
Bullish
DE:ZA71 Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.23%
12-Months-Change
Fundamentals
Return on Equity
-137.39%
Trailing 12-Months
Asset Growth
10.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Larimar Therapeutics, Inc.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
ZA71 Stock 12 Month Forecast
Average Price Target
€14.54
▲(320.30% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―